Moleculin Biotech, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Moleculin Biotech, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 4,091% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 94% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.4 times its market value (net cash). Higher than 93% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-165.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 90% of Healthcare companies in United States.
Cash Cushion Ratio
1.4× cashCash, after subtracting all debt, is 1.4 times its market value (net cash).
Higher than 93% of Healthcare companies in United States.
Tangible Assets Ratio
50%Of every $100 the company owns, $50 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 81% of Healthcare companies in United States.
Tangible Net Worth Ratio
26%Of every $100 of net worth, $26 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 63% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Moleculin Biotech, Inc. owes $0.45 for every $1 it owns. Moleculin Biotech, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.0Investors pay $0.0 for every $1 of Moleculin Biotech, Inc.'s yearly profit, lower than 97% of Healthcare companies in United States.
P/B ratio
0.52The share price is 0.52 times Moleculin Biotech, Inc.'s book value per share, lower than 91% of Healthcare companies in United States.
Market cap
$6 MThe total market value of all of Moleculin Biotech, Inc.'s shares at today's price (share price × number of shares), smaller than 91% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$12 MWhat Moleculin Biotech, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$11.37Net worth divided by the number of shares. The share price of $5.89 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-1371.6%Moleculin Biotech, Inc. lost 1371.6% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
Owes vs Owns
0.45×Moleculin Biotech, Inc. owes $0.45 for every $1 it owns (low), higher than 52% of Healthcare companies in United States.
Dividend yield
NoneMoleculin Biotech, Inc. does not currently pay a dividend.
Profit growth
LossMoleculin Biotech, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashMoleculin Biotech, Inc. held $9 M more cash than debt (net cash) at Dec 2025.
Questions
What is Moleculin Biotech, Inc.'s P/E ratio?
Investors pay $0.0 for every $1 of Moleculin Biotech, Inc.'s yearly profit, lower than 97% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Moleculin Biotech, Inc.: $6 M ÷ $12 M (30 Jun 2026) = 0.5.
What is Moleculin Biotech, Inc.'s return on equity?
Moleculin Biotech, Inc. lost 1371.6% of its shareholders' money over the last year, lower than 98% of Healthcare companies in United States.
How much does Moleculin Biotech, Inc. owe compared with what it owns?
Moleculin Biotech, Inc. owes $0.45 for every $1 it owns (low), higher than 52% of Healthcare companies in United States.
Does Moleculin Biotech, Inc. pay a dividend?
No. Moleculin Biotech, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.